Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
30 October 2008 - 10:00PM
PR Newswire (US)
JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a
developer of oral delivery systems, announced today that its Chief
Executive Officer, Mr. Nadav Kidron, will be giving a company
presentation at the 10th Annual Rodman & Renshaw Healthcare
Conference at New York City's Palace Hotel on November 11. Mr.
Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II
Ballroom, located on the 4th floor of the hotel. "The Rodman &
Renshaw Conference will give Oramed an important platform to
present the accomplishments we have achieved in our development of
an oral insulin capsule and our unique position as a technology
pioneer in the field of oral delivery solutions," said Kidron. For
more information about Rodman & Renshaw and the upcoming
conference, please visit
http://www.rodmanandrenshaw.com/conferences. For more information
about Oramed Pharmaceuticals, please visit http://www.oramed.com/.
About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology
pioneer in the field of oral delivery solutions for drugs and
vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented
flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology
is based on over 25 years of research by top research scientists at
Jerusalem's Hadassah Medical Center. The Company's corporate and
R&D headquarters are based in Jerusalem. For more information,
please visit http://www.oramed.com/ Forward-looking statements Some
of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell:
+972-54-566-7713 Office: +972-2-566-0001 Email: Media Contacts:
Ruder Finn Israel for Oramed Matthew Krieger Cell: +972-54-467-6950
Office: +972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceticals
CONTACT: Company and Investor Relation Contacts: Oramed
Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office:
+972-2-566-0001, Email: ; Media Contacts: Ruder Finn Israel for
Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office:
+972-2-589-2003, Email:
Copyright